GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Cyclically Adjusted Price-to-FCF

Cangene (FRA:YGE) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Cangene Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cangene Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cangene's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Cyclically Adjusted Price-to-FCF Chart

Cangene Annual Data
Trend Jul04 Jul05 Jul06 Jul07 Jul08 Jul09 Jul10 Jul11 Jul12 Jul13
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cangene Quarterly Data
Jan09 Apr09 Jul09 Oct09 Jan10 Apr10 Jul10 Oct10 Jan11 Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cangene's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cangene's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cangene's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cangene's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cangene's Cyclically Adjusted Price-to-FCF falls into.



Cangene Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cangene's Cyclically Adjusted FCF per Share for the quarter that ended in Oct. 2013 is calculated as:

For example, Cangene's adjusted Free Cash Flow per Share data for the three months ended in Oct. 2013 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Oct. 2013 (Change)*Current CPI (Oct. 2013)
=-0.078/97.1820*97.1820
=-0.078

Current CPI (Oct. 2013) = 97.1820.

Cangene Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200401 0.103 81.617 0.123
200404 -0.046 82.249 -0.054
200407 0.088 82.960 0.103
200410 -0.130 83.118 -0.152
200501 -0.076 83.197 -0.089
200504 0.021 84.224 0.024
200507 -0.025 84.619 -0.029
200510 -0.098 85.252 -0.112
200601 -0.059 85.489 -0.067
200604 0.099 86.279 0.112
200607 -0.015 86.595 -0.017
200610 0.013 86.121 0.015
200701 -0.022 86.437 -0.025
200704 -0.079 88.175 -0.087
200707 -0.063 88.491 -0.069
200710 0.020 88.175 0.022
200801 0.021 88.333 0.023
200804 -0.018 89.676 -0.020
200807 0.166 91.493 0.176
200810 0.011 90.466 0.012
200901 -0.046 89.281 -0.050
200904 -0.055 89.992 -0.059
200907 0.544 90.624 0.583
200910 -0.181 90.545 -0.194
201001 -0.039 90.940 -0.042
201004 0.049 91.651 0.052
201007 0.111 92.283 0.117
201010 -0.173 92.757 -0.181
201101 0.003 93.074 0.003
201104 0.096 94.654 0.099
201107 0.157 94.812 0.161
201110 -0.071 95.444 -0.072
201201 -0.054 95.365 -0.055
201204 0.107 96.550 0.108
201207 -0.093 95.997 -0.094
201210 -0.021 96.550 -0.021
201301 0.028 95.839 0.028
201304 0.038 96.945 0.038
201307 0.092 97.261 0.092
201310 -0.078 97.182 -0.078

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cangene  (FRA:YGE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cangene Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cangene's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cangene (FRA:YGE) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines